» Articles » PMID: 36991106

Magnetic Resonance Brain Volumetry Biomarkers of CLN2 Batten Disease Identified with Miniswine Model

Overview
Journal Sci Rep
Specialty Science
Date 2023 Mar 29
PMID 36991106
Authors
Affiliations
Soon will be listed here.
Abstract

Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease (Batten disease) is a rare pediatric disease, with symptom development leading to clinical diagnosis. Early diagnosis and effective tracking of disease progression are required for treatment. We hypothesize that brain volumetry is valuable in identifying CLN2 disease at an early stage and tracking disease progression in a genetically modified miniswine model. CLN2 miniswine and wild type controls were evaluated at 12- and 17-months of age, correlating to early and late stages of disease progression. Magnetic resonance imaging (MRI) T1- and T2-weighted data were acquired. Total intercranial, gray matter, cerebrospinal fluid, white matter, caudate, putamen, and ventricle volumes were calculated and expressed as proportions of the intracranial volume. The brain regions were compared between timepoints and cohorts using Gardner-Altman plots, mean differences, and confidence intervals. At an early stage of disease, the total intracranial volume (- 9.06 cm), gray matter (- 4.37% 95 CI - 7.41; - 1.83), caudate (- 0.16%, 95 CI - 0.24; - 0.08) and putamen (- 0.11% 95 CI - 0.23; - 0.02) were all notably smaller in CLN2 miniswines versus WT, while cerebrospinal fluid was larger (+ 3.42%, 95 CI 2.54; 6.18). As the disease progressed to a later stage, the difference between the gray matter (- 8.27%, 95 CI - 10.1; - 5.56) and cerebrospinal fluid (+ 6.88%, 95 CI 4.31; 8.51) continued to become more pronounced, while others remained stable. MRI brain volumetry in this miniswine model of CLN2 disease is sensitive to early disease detection and longitudinal change monitoring, providing a valuable tool for pre-clinical treatment development and evaluation.

Citing Articles

Enzyme Replacement Therapy for CLN2 Disease: MRI Volumetry Shows Significantly Slower Volume Loss Compared with a Natural History Cohort.

Gaur P, Gissen P, Biswas A, Mankad K, Sudhakar S, DArco F AJNR Am J Neuroradiol. 2024; 45(11):1791-1797.

PMID: 38977290 PMC: 11543065. DOI: 10.3174/ajnr.A8408.

References
1.
Norris C, Lisinski J, McNeil E, VanMeter J, VandeVord P, LaConte S . MRI brain templates of the male Yucatan minipig. Neuroimage. 2021; 235:118015. DOI: 10.1016/j.neuroimage.2021.118015. View

2.
Kielar C, Maddox L, Bible E, Pontikis C, Macauley S, Griffey M . Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis. 2006; 25(1):150-62. PMC: 1866219. DOI: 10.1016/j.nbd.2006.09.001. View

3.
Kovacs K, Patel S, Orlin A, Kim K, Van Everen S, Conner T . Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease. Ophthalmol Retina. 2020; 4(7):728-736. PMC: 7354207. DOI: 10.1016/j.oret.2020.01.011. View

4.
Tereshchenko A, Magnotta V, Epping E, Mathews K, Espe-Pfeifer P, Martin E . Brain structure in juvenile-onset Huntington disease. Neurology. 2019; 92(17):e1939-e1947. PMC: 6511077. DOI: 10.1212/WNL.0000000000007355. View

5.
Katz M, Tecedor L, Chen Y, Williamson B, Lysenko E, Wininger F . AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease. Sci Transl Med. 2015; 7(313):313ra180. PMC: 4968409. DOI: 10.1126/scitranslmed.aac6191. View